Patents by Inventor Harold V. Meyers

Harold V. Meyers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220031665
    Abstract: Disclosed are Nanoformulated compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL- and related cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Application
    Filed: November 5, 2019
    Publication date: February 3, 2022
    Inventors: Shaker A. Mousa, Nabil A. Elshourbagy, Harold V. Meyers, Sherin Salaheldin Abdel-Meguid
  • Patent number: 10947220
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: March 16, 2021
    Assignee: SHIFA BIOMEDICAL CORPORATION
    Inventors: Sherin Salaheldin Abdel-Meguid, Nabil A. Elshourbagy, Harold V. Meyers, Shaker A. Mousa
  • Patent number: 10899748
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: January 26, 2021
    Assignee: SHIFA BIOMEDICAL CORPORATION
    Inventors: Sherin Salaheldin Abdel-Meguid, Nabil A. Elshourbagy, Harold V. Meyers, Shaker A. Mousa
  • Publication number: 20200262822
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Application
    Filed: May 6, 2020
    Publication date: August 20, 2020
    Inventors: Sherin Salaheldin Abdel-Meguid, Nabil A. Elshourbagy, Harold V. Meyers, Shaker A. Mousa
  • Publication number: 20190270729
    Abstract: Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.
    Type: Application
    Filed: June 19, 2017
    Publication date: September 5, 2019
    Inventors: Sherin Salaheldin Abdel-Meguid, Nabil A. Elshourbagy, Harold V. Meyers, Shaker A. Mousa
  • Publication number: 20080146811
    Abstract: The invention provides compounds, pharmaceutical compositions, and methods for the treatment of thromboembolic disorders, such as, for example, arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, or thromboembolic disorders in the chambers of the heart.
    Type: Application
    Filed: July 22, 2005
    Publication date: June 19, 2008
    Inventors: Hongfeng Deng, Jian Lin, Zihong Guo, Harold V. Meyers, Sherin S. Abdel-Meguid, Robert E. Babine
  • Patent number: 7217794
    Abstract: The present invention provides compounds that inhibit Factor XIa and methods of preventing or treating undesired thrombosis by administering a compound of the invention to a mammal. The invention also provides three-dimensional structures of Factor XIa and methods for designing or selecting additional Factor XIa inhibitors using these structures.
    Type: Grant
    Filed: April 2, 2004
    Date of Patent: May 15, 2007
    Assignee: Daiamed, Inc.
    Inventors: Sherin S. Abdel-Meguid, Robert E. Babine, Hongfeng Deng, Lei Jin, Jian Lin, Scott R. Magee, Harold V. Meyers, Pramod Pandey, Michael J. Rynkiewicz, David T. Weaver, Zihong Gho, Thomas D. Bannister
  • Patent number: 5665774
    Abstract: This invention relates to a novel class of immunosuppressive compounds having an affinity for the FK-506 binding protein (FKBP). Once bound to this protein, the immunosuppressive compounds inhibit the prolyl peptidyl cis-trans isomerase (rotamase) activity of the FKBP and inhibit T cell activation. As such, the compounds of this invention can be used as immunosuppressive drugs to prevent or significantly reduce graft rejection in bone marrow and organ transplantations and for use in the treatment of a wide variety of autoimmune diseases in humans and other mammals.
    Type: Grant
    Filed: March 8, 1993
    Date of Patent: September 9, 1997
    Inventors: David M. Armistead, Joshua S. Boger, Harold V. Meyers, Jeffrey O. Saunders, Roger D. Tung
  • Patent number: 5622970
    Abstract: This invention relates to a novel class of immunosuppressive compounds having an affinity for the FK-506 binding protein (FKBP). Once bound to this protein, the immunosuppressive compounds inhibit the prolyl peptidyl cis-trans isomerase (rotamase) activity of the FKBP and inhibit T cell activation. As such, the compounds of this invention can be used as immunosuppressive drugs to prevent or significantly reduce graft rejection in bone marrow and organ transplantations and for use in the treatment of a wide variety of autoimmune diseases in humans and other mammals.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: April 22, 1997
    Assignee: Vertex Pharmaceuticals, Incorporated
    Inventors: David A. Armistead, Joshua S. Boger, Harold V. Meyers, Jeffrey O. Saunders, Roger D. Tung
  • Patent number: 5516797
    Abstract: This invention relates to a novel class of immunosuppressive compounds having an affinity for the FK-506 binding protein (FKBP). Once bound to this protein, the immunosuppressive compounds inhibit the prolyl peptidyl cis-trans isomerase (rotamase) activity of the FKBP and inhibit T cell activation. As such, the compounds of this invention can be used as immunosuppressive drugs to prevent or significantly reduce graft rejection in bone marrow and organ transplantations and for use in the treatment of a wide variety of autoimmune diseases in humans and other mammals.
    Type: Grant
    Filed: April 11, 1994
    Date of Patent: May 14, 1996
    Assignee: Vertex Pharmaceuticals, Incorporated
    Inventors: David M. Armistead, Joshua S. Boger, Harold V. Meyers, Jeffrey O. Saunders, Roger D. Tung
  • Patent number: 5492836
    Abstract: The invention provides a method for determining the structure of a carbohydrate sample, comprising perbenzoylating a carbohydrate sample with a perbenzoylating agent to protect free hydroxyl groups in the carbohydrate sample; cleaving the glycosidic linkages of the perbenzoylated carbohydrate sample by contacting the carbohydrate sample with an amount of BrCH.sub.2 COBr/H.sub.2 O effective to cleave the carbohydrate sample; treating the resulting product with AgOAc and methanol or AgOTf/TMU and methanol to effect glycosidation; treating the resulting product with thiourea to remove bromoacetate groups; subjecting the resulting product to effect methoxycinnamoylation of free hydroxyl groups; separating the resulting benzoates with high-pressure liquid chromatography; performing mass, ultraviolet and circular dichroic spectroscopy on the separated benzoates; and comparing the spectra so obtained with reference spectra or calculated values to identify the structure of the carbohydrate.
    Type: Grant
    Filed: March 6, 1991
    Date of Patent: February 20, 1996
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Koji Nakanishi, Harold V. Meyers, William T. Wiesler, Makoto Ojika
  • Patent number: 5330993
    Abstract: This invention relates to a novel class of immunosuppressive compounds having an affinity for the FK-506 binding protein (FKBP). Once bound to this protein, the immunosuppressive compounds inhibit the prolyl peptidyl cis-trans isomerase (rotamass) activity of the FKBP and inhibit T cell activation. As such, the compounds of this invention can be used as immunosuppressive drugs to prevent or significantly reduce graft rejection in bone marrow and organ transplantations and for use in the treatment of a wide variety of autoimmune diseases in humans and other mammals.
    Type: Grant
    Filed: July 2, 1991
    Date of Patent: July 19, 1994
    Assignee: Vertex Pharmaceuticals, Inc.
    Inventors: David M. Armistead, Joshua S. Boger, Harold V. Meyers, Jeffrey O. Saunders, Roger D. Tung
  • Patent number: 5192773
    Abstract: This invention relates to a novel class of immunosuppressive compounds having an affinity for the FK-506 binding protein (FKBP). Once bound to this protein, the immunosuppressive compounds inhibit the prolyl peptidyl cis-trans isomerase (rotamase) activity of the FKBP and inhibit T cell activation. As such, the compounds of this invention can be used as immunosuppressive drugs to prevent or significantly reduce graft rejection in bone marrow and organ transplantations and for use in the treatment of a wide variety of autoimmune diseases in humans and other mammals.
    Type: Grant
    Filed: July 2, 1990
    Date of Patent: March 9, 1993
    Assignee: Vertex Pharmaceuticals, Inc.
    Inventors: David A. Armistead, Joshua S. Boger, Harold V. Meyers, Jeffrey O. Saunders, Roger D. Tung